Post‑TAVR Follow‑Up and Management Guidelines
Follow‑Up Schedule and Care Coordination
- The ACC recommends a structured follow‑up pathway: TAVR team review at 30 days, primary cardiologist visits at 6 months and then annually, and primary‑care evaluation at 3 months and as needed, with baseline transthoracic echocardiography and 12‑lead ECG performed at 30 days and repeated yearly. 1
- During the first 30 days the TAVR team holds primary responsibility for detecting and managing procedural complications. 1
- Baseline echocardiography and ECG within the first month are required to document prosthetic‑valve function and identify new conduction disturbances. 2
- If bradycardia emerges, a 24‑hour Holter monitor should be considered. 3
- After the initial month, the primary cardiologist assumes care, seeing the patient at 6 months and subsequently each year. 1
- Visit frequency should be increased when moderate or severe paravalvular leak or any change in clinical status is identified. 2
Antithrombotic Management
- The ACC advises lifelong low‑dose aspirin (75–100 mg daily) combined with clopidogrel 75 mg daily for 3–6 months after TAVR. 3
- In patients with atrial fibrillation or a high risk of venous thromboembolism, warfarin targeting an INR of 2.0–2.5 may be added. 3
- For patients already on chronic oral anticoagulation for atrial fibrillation, low‑dose aspirin should be continued while additional antiplatelet agents are avoided to limit bleeding risk. 2
- Triple antithrombotic therapy (anticoagulant + dual antiplatelet) is discouraged in this elderly population because of a prohibitive bleeding risk. 2
Diagnostic Surveillance
Echocardiography
- Perform a transthoracic echocardiogram at 30 days to establish a baseline of valve hemodynamics, then repeat annually. 3
- Increase imaging frequency if moderate or severe paravalvular aortic regurgitation is detected or if the patient’s clinical condition changes. 2
Electrocardiographic Monitoring
- Obtain a 12‑lead ECG at 30 days and annually thereafter to monitor for new conduction abnormalities. 3
Management of Concurrent Cardiovascular Conditions
- The ACC recommends active management of coronary artery disease, hypertension, heart failure, and arrhythmias (particularly atrial fibrillation) in all post‑TAVR patients. 3
Non‑Cardiac Comorbidities and Readmissions
- Readmission rates exceed 40 % within the first year after TAVR, with approximately 60 % of these readmissions driven by non‑cardiac causes such as respiratory infections, other infections, and bleeding events. [1][3]
- Annual (or as‑needed) assessment of pulmonary, renal, gastrointestinal, and neurological function is advised. 3
Endocarditis Prophylaxis and Dental Care
- Per AHA/ACC prosthetic‑valve guidelines, antibiotic prophylaxis should be administered before dental procedures that carry a risk of bacteremia. 3
Rehabilitation, Lifestyle Modification, and Risk‑Factor Reduction
- The ACC endorses enrollment in cardiac rehabilitation programs and promotion of regular physical activity after TAVR. [1][3]
- Early physical and occupational therapy assessments are recommended to prevent deconditioning. 1
- Ongoing cardiac risk‑factor reduction (e.g., smoking cessation, blood‑pressure control, lipid management) and healthy‑lifestyle counseling are essential components of post‑procedural care. 1
Monitoring for Procedural Complications
Vascular Access Site
- Surveillance of the vascular access site for bleeding, hematoma, or pseudo‑aneurysm formation should be performed during the early post‑procedure period. 1
Long‑Term Outcomes
- Approximately 30 % of TAVR recipients die within three years, with the majority of deaths after the first six months attributable to non‑cardiac causes. 1
- Structural valve deterioration occurs in about 3.3 % of patients, and bioprosthetic valve failure is observed in roughly 2.4 % during long‑term follow‑up. 1
Care Coordination
- Effective coordination among the TAVR team, the primary cardiologist, and the primary‑care physician is critical to optimize outcomes after TAVR. 3
Post-TAVR Follow-Up Care
Follow-Up Schedule
- The American College of Cardiology recommends that patients after TAVR should be seen by the TAVR team at 30 days, by their primary cardiologist at 6 months and then annually, and by their primary care physician at 3 months and as needed thereafter, with echocardiography and ECG performed at 30 days and annually 4
- TAVR team evaluation at 30 days is essential to diagnose and monitor any procedural complications, as recommended by the American College of Cardiology 4, 5
- Baseline echocardiogram and ECG must be obtained during the initial 30-day period to document valve function and any conduction abnormalities, according to the American College of Cardiology 4, 5
Antithrombotic Management
- The American College of Cardiology recommends aspirin 75-100 mg daily lifelong 4
- The American College of Cardiology suggests clopidogrel 75 mg daily for 3-6 months 4
- Consider warfarin (INR 2.0-2.5) if at risk for atrial fibrillation or venous thromboembolism, as recommended by the American College of Cardiology 4
- In patients already on oral anticoagulation for atrial fibrillation or other indications, it is reasonable to continue low-dose aspirin but avoid additional antiplatelet therapy if possible to minimize bleeding risk, according to the American College of Cardiology 6
Diagnostic Monitoring
- Echocardiography should be performed at 30 days, then annually (if needed), as recommended by the American College of Cardiology 4
- Increase frequency of echocardiography if significant paravalvular leak or changes in clinical status occur, according to the American College of Cardiology 5
- Monitor for aortic regurgitation, which is typically paravalvular and mild in most patients, as recommended by the American College of Cardiology 6
- ECG should be performed at 30 days and annually, as recommended by the American College of Cardiology 4
- Consider 24-hour Holter monitoring if bradycardia is present, according to the American College of Cardiology 4
Management of Concurrent Conditions
- The primary cardiologist should actively manage coronary artery disease, as recommended by the American College of Cardiology 5
- Management of diabetes and dyslipidemia is recommended, according to the American College of Cardiology 6
Additional Care Elements
- Encourage optimal dental hygiene, as recommended by the American College of Cardiology 4
- Antibiotic prophylaxis should be performed per AHA/ACC guidelines, according to the American College of Cardiology 4
- Promote cardiac rehabilitation and physical activity as appropriate, as recommended by the American College of Cardiology 4
- Cardiac risk factor reduction and healthy lifestyle promotion are recommended, according to the American College of Cardiology 4
- Provide comprehensive patient instructions and education at discharge, as recommended by the American College of Cardiology 4
- Ensure patients understand warning signs requiring urgent evaluation, according to the American College of Cardiology 4
Dental Management After Transcatheter Aortic Valve Replacement (TAVR)
Timing of Dental Procedures
- Invasive dental procedures may be performed immediately after TAVR when appropriate antibiotic prophylaxis is given; current ACC/AHA expert consensus does not require a mandatory waiting period. 7, 8
Antibiotic Prophylaxis
- Lifelong antibiotic prophylaxis is required for any invasive dental work in TAVR patients; the standard regimen is amoxicillin 2 g orally 30–60 minutes before the procedure (per AHA guidelines). This recommendation is a Class I, Level C (expert consensus) recommendation. 7, 8
Routine Dental Care
- Routine dental examinations and cleanings can be performed without delay and without antibiotic prophylaxis. 7, 8
Invasive Dental Procedures
- For extractions, periodontal therapy, implants, or other invasive dental interventions, standard AHA endocarditis prophylaxis must be administered. 7, 8
Antithrombotic Therapy Considerations
- All TAVR patients should be on lifelong aspirin (75–100 mg daily); clopidogrel (75 mg daily) is added for 3–6 months post‑procedure.
- If a patient is within the first 30 days after TAVR, coordination with the cardiology team is advised to confirm that no early procedural complications are present.
- For high‑bleeding‑risk invasive dental procedures performed 3–6 months after TAVR (when dual antiplatelet therapy may still be present), temporary discontinuation of clopidogrel should be discussed with cardiology, while aspirin must never be stopped. 7, 8
Anticoagulation Management
- Patients on chronic warfarin (e.g., for atrial fibrillation with target INR 2.0–2.5) should be managed according to standard dental anticoagulation protocols. 7, 8
Oral Hygiene Promotion
- Optimal dental hygiene should be encouraged continuously throughout the post‑TAVR period to reduce bacterial load and endocarditis risk. 7, 8
Practical Timing Recommendations
- When feasible, scheduling elective invasive dental work after 3–6 months post‑TAVR can simplify bleeding management by allowing cessation of clopidogrel. 7, 8
Clinical Prioritization
- Do not delay necessary dental treatment for the sake of “safety”; the risk of untreated dental infection may outweigh procedural risks. 7, 8
Communication with Dental Providers
- Provide explicit written instructions to the patient’s dentist regarding the mandatory prophylactic antibiotic requirement for invasive procedures. 7, 8